-
Je něco špatně v tomto záznamu ?
Variations and obstacles in the use of coagulation factor concentrates for major trauma bleeding across Europe: outcomes from a European expert meeting
V. Černý, M. Maegele, V. Agostini, D. Fries, SR. Leal-Noval, G. Nardai, G. Nardi, A. Östlund, H. Schöchl
Jazyk angličtina Země Německo
Typ dokumentu časopisecké články, přehledy
NLK
ProQuest Central
od 2007-02-01 do Před 1 rokem
CINAHL Plus with Full Text (EBSCOhost)
od 2007-02-01 do Před 1 rokem
Nursing & Allied Health Database (ProQuest)
od 2007-02-01 do Před 1 rokem
Health & Medicine (ProQuest)
od 2007-02-01 do Před 1 rokem
- MeSH
- fibrinogen terapeutické užití MeSH
- hemostatika * terapeutické užití MeSH
- koagulační faktory farmakologie terapeutické užití MeSH
- koagulopatie * terapie MeSH
- krvácení farmakoterapie etiologie MeSH
- kyselina tranexamová * terapeutické užití MeSH
- lidé MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
PURPOSE: Trauma is a leading cause of mortality, with major bleeding and trauma-induced coagulopathy (TIC) contributing to negative patient outcomes. Treatments for TIC include tranexamic acid (TXA), fresh frozen plasma (FFP), and coagulation factor concentrates (CFCs, e.g. prothrombin complex concentrates [PCCs] and fibrinogen concentrate [FCH]). Guidelines for TIC management vary across Europe and a clear definition of TIC is still lacking. METHODS: An advisory board involving European trauma experts was held on 02 February 2019, to discuss clinical experience in the management of trauma-related bleeding and recommendations from European guidelines, focusing on CFC use (mainly FCH). This review summarises the discussions, including TIC definitions, gaps in the guidelines that affect their implementation, and barriers to use of CFCs, with suggested solutions. RESULTS: A definition of TIC, which incorporates clinical (e.g. severe bleeding) and laboratory parameters (e.g. low fibrinogen) is suggested. TIC should be treated immediately with TXA and FCH/red blood cells; subsequently, if fibrinogen ≤ 1.5 g/L (or equivalent by viscoelastic testing), treatment with FCH, then PCC (if bleeding continues) is suggested. Fibrinogen concentrate, and not FFP, should be administered as first-line therapy for TIC. Several initiatives may improve TIC management, with improved medical education of major importance; generation of new and stronger data, simplified clinical practice guidance, and improved access to viscoelastic testing are also critical factors. CONCLUSIONS: Management of TIC is challenging. A standard definition of TIC, together with initiatives to facilitate effective CFC administration, may contribute to improved patient care and outcomes.
AUVA Trauma Centre Salzburg Salzburg Austria
Critical Care Division University Hospital 'Virgen del Rocio' Seville Spain
Department of Anesthesia and Intensive Care Rimini Hospital Rimini Italy
IRCCS Ospedale Policlinico San Martino Genova Italy
Perioperative Medicine and Intensive Care Karolinska University Hospital Solna Stockholm Sweden
Péterfy Sándor Str Hospital and Trauma Center Budapest Hungary
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22018957
- 003
- CZ-PrNML
- 005
- 20220804135220.0
- 007
- ta
- 008
- 220720s2022 gw f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s00068-020-01563-2 $2 doi
- 035 __
- $a (PubMed)33399876
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gw
- 100 1_
- $a Černý, Vladimir $u Department of Anesthesiology, Perioperative Medicine and Intensive Care, JE Purkinje University, Usti Nad Labem, Masaryk Hospital, Prague, Czech Republic. cernyvla1960@gmail.com
- 245 10
- $a Variations and obstacles in the use of coagulation factor concentrates for major trauma bleeding across Europe: outcomes from a European expert meeting / $c V. Černý, M. Maegele, V. Agostini, D. Fries, SR. Leal-Noval, G. Nardai, G. Nardi, A. Östlund, H. Schöchl
- 520 9_
- $a PURPOSE: Trauma is a leading cause of mortality, with major bleeding and trauma-induced coagulopathy (TIC) contributing to negative patient outcomes. Treatments for TIC include tranexamic acid (TXA), fresh frozen plasma (FFP), and coagulation factor concentrates (CFCs, e.g. prothrombin complex concentrates [PCCs] and fibrinogen concentrate [FCH]). Guidelines for TIC management vary across Europe and a clear definition of TIC is still lacking. METHODS: An advisory board involving European trauma experts was held on 02 February 2019, to discuss clinical experience in the management of trauma-related bleeding and recommendations from European guidelines, focusing on CFC use (mainly FCH). This review summarises the discussions, including TIC definitions, gaps in the guidelines that affect their implementation, and barriers to use of CFCs, with suggested solutions. RESULTS: A definition of TIC, which incorporates clinical (e.g. severe bleeding) and laboratory parameters (e.g. low fibrinogen) is suggested. TIC should be treated immediately with TXA and FCH/red blood cells; subsequently, if fibrinogen ≤ 1.5 g/L (or equivalent by viscoelastic testing), treatment with FCH, then PCC (if bleeding continues) is suggested. Fibrinogen concentrate, and not FFP, should be administered as first-line therapy for TIC. Several initiatives may improve TIC management, with improved medical education of major importance; generation of new and stronger data, simplified clinical practice guidance, and improved access to viscoelastic testing are also critical factors. CONCLUSIONS: Management of TIC is challenging. A standard definition of TIC, together with initiatives to facilitate effective CFC administration, may contribute to improved patient care and outcomes.
- 650 12
- $a koagulopatie $x terapie $7 D001778
- 650 _2
- $a koagulační faktory $x farmakologie $x terapeutické užití $7 D001779
- 650 _2
- $a fibrinogen $x terapeutické užití $7 D005340
- 650 _2
- $a krvácení $x farmakoterapie $x etiologie $7 D006470
- 650 12
- $a hemostatika $x terapeutické užití $7 D006490
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a kyselina tranexamová $x terapeutické užití $7 D014148
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Maegele, Marc $u Department of Trauma and Orthopedic Surgery, Institute for Research in Operative Medicine (IFOM), University Witten/Herdecke, Cologne-Merheim Medical Center (CMMC), Cologne, Germany
- 700 1_
- $a Agostini, Vanessa $u IRCCS Ospedale Policlinico San Martino, Genova, Italy
- 700 1_
- $a Fries, Dietmar $u Department for General and Surgical Critical Care Medicine, Medical University Innsbruck, Innsbruck, Austria
- 700 1_
- $a Leal-Noval, Santiago R $u Critical Care Division, University Hospital 'Virgen del Rocio', Seville, Spain
- 700 1_
- $a Nardai, Gábor $u Péterfy Sándor Str. Hospital and Trauma Center, Budapest, Hungary
- 700 1_
- $a Nardi, Giuseppe $u Department of Anesthesia and Intensive Care, Rimini Hospital, Rimini, Italy
- 700 1_
- $a Östlund, Anders $u Perioperative Medicine and Intensive Care, Karolinska University Hospital Solna, Stockholm, Sweden
- 700 1_
- $a Schöchl, Herbert $u AUVA Trauma Centre Salzburg, Salzburg, Austria
- 773 0_
- $w MED00157536 $t European journal of trauma and emergency surgery : official publication of the European Trauma Society $x 1863-9941 $g Roč. 48, č. 2 (2022), s. 763-774
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/33399876 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220720 $b ABA008
- 991 __
- $a 20220804135214 $b ABA008
- 999 __
- $a ok $b bmc $g 1822516 $s 1170200
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 48 $c 2 $d 763-774 $e 20210105 $i 1863-9941 $m European journal of trauma and emergency surgery $n Eur J Trauma Emerg Surg $x MED00157536
- LZP __
- $a Pubmed-20220720